Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Drug-Resistant Tuberculosis | Kisho | Kisho

Back to Drug-Resistant Tuberculosis

Drug-Resistant Tuberculosis — NIH Grants & Funding

Active and recent NIH-funded research on Drug-Resistant Tuberculosis. Data from NIH RePORTER, last 36 months.

MONDO:0041806

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Drug-Resistant Tuberculosis has a robust NIH research funding landscape with 109 funded grants and $149.8M in total funding over the period.

109funded grants from NIH

Portfolio: $65.0MCumulative: $149.8M66 active43 completed125 PIs56 institutions

+1% YoY(FY2024 vs FY2025)

12 new grants started in the last 12 months.

By Research Theme

Translational

Basic Science

Clinical

Biomarker / Dx

Epi / Nat. History

Medical Device

2 additional grants classified as “Other” (multi-disciplinary, infrastructure, etc.).

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$8.3M

FY22

$38.5M

FY23

$43.1M

FY24

$43.4M

FY25

$16.5M

FY26

By Funding Mechanism

R01

R21

N01

K08

R44

R41

Adjacent Research(34 grants)

These grants mention Drug-Resistant Tuberculosis as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(34)

OtherY01Completed

NIAID Regional Prospective Observational Research in Tuberculosis (RePORT) and Hepatitis Diagnostics

Unknown PI·NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

$6,500,000 (FY2023)

NIH RePORTER

OtherR01Active

Advancing Apoptosis-Inducing Agents as Host-Directed Therapy for TB

Hamacher-Brady, Anne et al.·JOHNS HOPKINS UNIVERSITY·BALTIMORE, MD

$2,922,220 (FY2025)

NIH RePORTER

OtherR01Active

FEND-TB

Alland, David et al.·RUTGERS BIOMEDICAL AND HEALTH SCIENCES·Newark, NJ

$2,593,818 (FY2025)

NIH RePORTER

OtherR01Active

Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II)

Cattamanchi, Adithya et al.·UNIVERSITY OF CALIFORNIA, SAN FRANCISCO·SAN FRANCISCO, CA

$2,408,741 (FY2025)

NIH RePORTER

OtherR01Active

Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB

Baldwin, Susan et al.·SEATTLE CHILDREN'S HOSPITAL·SEATTLE, WA

$978,349 (FY2025)

NIH RePORTER

OtherUM1Active

GHESKIO Clinical Trials Unit

PAPE, JEAN·GHESKIO CENTER·PORT-AU-PRINCE

$879,162 (FY2026)

NIH RePORTER

OtherR01Active

Inhalational therapy with spectinamides within new regimens of TB therapy

Gonzalez-Juarrero, Mercedes et al.·COLORADO STATE UNIVERSITY·FORT COLLINS, CO

$788,086 (FY2025)

NIH RePORTER

OtherR01Active

Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.

Alland, David·RUTGERS BIOMEDICAL AND HEALTH SCIENCES·Newark, NJ

$782,450 (FY2026)

NIH RePORTER

OtherR01Active

Membrane Protein Complexes in the M. Tuberculosis Divisome: Structures and Interactions

CROSS, TIMOTHY et al.·FLORIDA STATE UNIVERSITY·TALLAHASSEE, FL

$668,549 (FY2026)

NIH RePORTER

OtherR37Active

Pattern Recognition Receptors and Autophagy in Mtb Control in AIDS

DERETIC, VOJO·UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR·ALBUQUERQUE, NM

$571,773 (FY2025)

NIH RePORTER

Kisho

Drug-Resistant Tuberculosis — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Adjacent Research(34 grants)

Other(34)

NIAID Regional Prospective Observational Research in Tuberculosis (RePORT) and Hepatitis Diagnostics

Advancing Apoptosis-Inducing Agents as Host-Directed Therapy for TB

FEND-TB

Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II)

Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB

GHESKIO Clinical Trials Unit

Inhalational therapy with spectinamides within new regimens of TB therapy

Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.

Membrane Protein Complexes in the M. Tuberculosis Divisome: Structures and Interactions

Pattern Recognition Receptors and Autophagy in Mtb Control in AIDS

Top Funded Institutions

Top Principal Investigators